Personalized Medicine for Treatment-Resistant Schizophrenia May Hold Key to Improved Care

Strategic Insights -

According to research from the University Medical School, treatment-resistant schizophrenia (TRS) affects up to one in three individuals with schizophrenia, associated with significant clinical, social, and economic burdens. A new report aims to outline current knowledge on the molecular and cellular basis of TRS, shifting the traditional dopamine hypothesis toward a more comprehensive model including multiple immune, metabolic, and synaptic factors. Understanding the possible interplay of these complex mechanisms may lead to the identification of potential biomarkers for predicting antipsychotic response and the development of more targeted treatments.

Key Takeaways:

  • Treatment-resistant schizophrenia affects up to one in three individuals with schizophrenia, impacting clinical, social, and economic burdens.
  • Current knowledge on the molecular and cellular basis of TRS focuses on alterations in glutamate signaling, imbalances between excitatory and inhibitory activity, disruptions in D-amino acid metabolism, and evidence of neuroinflammation, oxidative stress, and mitochondrial or endoplasmic reticulum dysfunction.
  • Multimodal brain imaging studies reveal differences in brain structure, white matter integrity, and network connectivity between TRS and treatment-responsive individuals.
  • A more comprehensive model of TRS includes multiple immune, metabolic, and synaptic factors, shifting from the traditional dopamine hypothesis.
  • Early recognition and a deeper biological insight into TRS are essential for improving care and guiding personalized therapeutic strategies.
  • The development of targeted treatments for TRS relies on understanding the complex interplay of biological mechanisms.
  • Potential biomarkers for predicting antipsychotic response may be identified through research on genomics, proteomics, metabolomics, preclinical models, and postmortem studies.
  • The University Medical School in Naples, Italy, is at the forefront of research on TRS and personalized medicine.

Statistics:

  • Up to 1 in 3 individuals with schizophrenia are affected by treatment-resistant schizophrnia.
  • Research suggests that multiple immune, metabolic, and synaptic factors contribute to TRS.
  • Multimodal brain imaging studies reveal differences in brain structure and network connectivity between TRS and treatment-responsive individuals.
  • The development of targeted treatments for TRS may be accelerated through understanding the complex interplay of biological mechanisms.

Sources:

  • International Journal of Molecular Sciences, "Molecular Underpinning of Treatment-resistant Schizophrenia: a Putative Different Neurobiology From Treatment-responsive Schizophrenia."
  • University Medical School Naples Federico Ii, Dept Neurosci Reprod Sci & Dent, Unit Treatment Resistant Psychosis, Section of Psychiatry, Lab Translat & Mol Psychiat, Via Pansini 5, I-80131 Naples, Italy.
  • Mdpi, St Alban-Anlage 66, Ch-4052 Basel, Switzerland.